Mesoblast (MESO) EBT Margin (2014 - 2023)
Mesoblast (MESO) posted EBT Margin of 1183.77% for Q2 2023, down 23.1% sequentially from 961.63% in Q1 2023, and down 22450.0% YoY from N/an in Q2 2022.
Powered by 
Analysis
Mesoblast (MESO) EBT Margin (2014 - 2023) Analysis & Trends
Mesoblast has reported EBT Margin for 10 years, with the latest figure at 1183.77% in Q2 2023.
- Quarterly EBT Margin fell 22450.0% year-over-year to 1183.77% in Q2 2023, while the trailing twelve-month figure through Jun 2023 was 1007.75% (down 11081.0% YoY) and the FY2025 annual result came in at 592.0%, up 90151.0% from the prior year.
- EBT Margin eased to 1183.77% in Q2 2023 per MESO's latest filing, from 961.63% in the prior quarter.
- Over five years, EBT Margin peaked at 136.72% in Q2 2020 and troughed at 2607.97% in Q1 2019.
- A 5-year average of 1102.7% and a median of 1084.99% in 2021 frame the typical range for EBT Margin.
- The widest YoY moves for EBT Margin: up 178057 bps in 2020, down 154055 bps in 2020.
- Over 5 years, EBT Margin stood at 1363.79% in 2019, then increased by 16 bps to 1143.15% in 2020, then soared by 36 bps to 736.0% in 2021, then plunged by 56 bps to 1150.75% in 2022, then decreased by 3 bps to 1183.77% in 2023.
- According to Business Quant data, EBT Margin over the past three periods registered 1183.77%, 961.63%, and 1150.75% for Q2 2023, Q1 2023, and Q4 2022 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 35.78% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -528.97% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 18.33% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 13.77% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -2.67% |
| 10 | Mesoblast | 2.24 Bn | 2.14 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2023 | -1,183.77% |
| Mar 31, 2023 | -961.63% |
| Dec 31, 2022 | -1,150.75% |
| Sep 30, 2022 | -1,127.01% |
| Jun 30, 2022 | 8,039.04% |
| Mar 31, 2022 | -1,061.51% |
| Dec 31, 2021 | -736.00% |
| Sep 30, 2021 | -631.80% |
| Jun 30, 2021 | 9,042.11% |
| Mar 31, 2021 | -1,389.71% |
| Dec 31, 2020 | -1,143.15% |
| Sep 30, 2020 | -1,936.70% |
| Mar 31, 2020 | -163.69% |
| Dec 31, 2019 | -949.28% |
| Sep 30, 2019 | -43.50% |
| Jun 30, 2019 | -1,215.20% |
| Mar 31, 2019 | -2,175.74% |
| Dec 31, 2018 | -1,468.93% |
| Sep 30, 2018 | -173.66% |
| Jun 30, 2018 | -1,285.59% |